Bruce Sands, MD
Gastroenterology · New York, NYNPI 1093706665
Payments from drug & device makers
Across 553 payments — averaging $5019.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$2M
- Pfizer$179K
- Takeda Pharmaceuticals U.S.A., Inc.$115K
- Eli Lilly$111K
- Merck$60K
- AbbVie$44K
- plus $293K from 28 others
Across 127 payments — averaging $1099.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$117K
- Sanofi US Services Inc.$13K
- Genentech, Inc.$4K
- F. Hoffmann-la Roche AG$2K
- Amgen$2K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$542
- plus $500 from 1 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 67 | $1,973,966 |
| Pfizer(2 entities) | 48 | $179,225 |
| Takeda Pharmaceuticals U.S.A., Inc. | 79 | $114,626 |
| Eli Lilly | 101 | $110,602 |
| Merck | 44 | $60,457 |
| AbbVie | 40 | $43,848 |
| E.r. Squibb & Sons, L.L.C. | 16 | $32,443 |
| Genentech, Inc. | 23 | $29,487 |
| Johnson & Johnson | 23 | $28,506 |
| Janssen Global Services, LLC | 16 | $26,724 |
| Gilead | 8 | $24,082 |
| GSK | 2 | $20,072 |
| Tanabe Pharma Corporation | 8 | $15,657 |
| Celltrion, Inc. | 6 | $15,255 |
| Boehringer Ingelheim International GmbH | 12 | $14,912 |
| Whitehall International Inc | 4 | $14,146 |
| Teva Pharmaceuticals USA, Inc. | 2 | $12,158 |
| Ironwood Pharmaceuticals, Inc | 6 | $10,438 |
| Amgen | 7 | $9,675 |
| Lilly USA, LLC | 5 | $8,050 |
| Astrazeneca UK Limited | 2 | $6,060 |
| Sanofi US Services Inc. | 2 | $5,152 |
| AstraZeneca | 2 | $4,200 |
| Janssen Scientific Affairs, LLC | 12 | $3,678 |
| Shire North American Group Inc | 1 | $3,500 |
| Celltrion USA Inc. | 3 | $3,112 |
| Novartis | 1 | $1,650 |
| Bristol Myers Squibb | 3 | $1,464 |
| Ferring Pharmaceuticals Inc. | 1 | $1,250 |
| Kyowa Kirin, Inc. | 1 | $650 |
| Ferring Pharmaceuticals AS | 2 | $638 |
| Boston Scientific | 4 | $186 |
| Anx Robotica Corp | 1 | $128 |
| Exact Sciences | 1 | $20 |
How this compares
$2,776,019 in reported general payments places this provider in the 95th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gastroenterology in New York
- David HudesmanNew York$3.6M
- Ellen ScherlNew York$2.9M
- Arun SwaminathNew York$2.7M
- Sonal KumarNew York$2.3M
- David Carr LockeNew York$2.1M
- Arthur KornbluthNew York$1.9M
- Ira JacobsonNew York$1.8M
- James MarionNew York$1.7M
- Jean Frederick ColombelNew York$1.6M
- Scott FriedmanNew York$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.